Gastric Emptying Time

2

Review clinical trials related to Gastric Emptying Time. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Intraoperative Pyloric Balloon Dilatation to Reduce Delayed Gastric Emptying After PPPD

Pylorus-preserving pancreatoduodenectomy (PPPD) is a standard surgical treatment for tumors of the pancreatic head and surrounding areas. However, it is frequently associated with delayed gastric emptying (DGE), a complication that can lead to nausea, vomiting, and prolonged hospital stays. This study is a randomized controlled trial designed to evaluate if a simple intraoperative maneuver (pneumatic balloon dilatation of the pylorus) can reduce the incidence of early postoperative vomiting and DGE. Participants will be randomly assigned to either the intervention group, receiving pyloric dilatation during surgery, or the control group, receiving standard surgery without dilatation. Researchers will monitor postoperative symptoms, gastric emptying function, and overall recovery to determine if this maneuver effectively improves patient outcomes.

Participants needed: 70
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Assiut UniversityUpdated: Mar 5, 2026
Eligibility criteria

Adult patients (≥18 years) scheduled for elective PPPD due to tumors of the panc... [+2]

Patients with prior gastric surgery, pyloric stenosis, or history of severe gast... [+3]

Status: Not yet recruiting

Gastric Emptying With Metoclopramide in GLP-1 Agonist Patients Undergoing Elective Surgery

This is a multicentre, investigator-blinded, randomised controlled trial evaluating whether the use of oral metoclopramide before surgery can reduce the amount of residual gastric content in patients who are taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss. These medications are known to slow down gastric emptying, which may increase the risk of pulmonary aspiration during anaesthesia. Patients will be randomly assigned to either receive metoclopramide 24 hours before surgery or continue with standard care. The primary outcome will be the presence or absence of residual gastric content on ultrasound before surgery. Secondary outcomes include nausea, vomiting, constipation, and any adverse effects of the medication.

Participants needed: 80
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Mater Misericordiae University HospitalUpdated: Aug 6, 2025Locations: 2
Eligibility criteria

Patients taking GLP-1 receptor agonists (for weight loss only) [+4]

Inability to provide informed consent [+9]